There have been only a few head-to-head studies comparing one drug to another in the field of psoriatic arthritis (PsA), although they are more prevalent in rheumatoid arthritis (RA). In the absence of direct comparisons to determine superiority or comparability in efficacy and safety between drugs, an alternative method, network meta-analysis (NMA), is gaining traction. This statistical methodology is increasingly reliable, sophisticated, and accepted by physicians and insurance companies when deciding treatment options and formulary inclusion.

In an interview with HCPLive, Philip J Mease, MD, a clinical professor at the University of Washington School of Medicine and director of rheumatology research at the Swedish Medical Center in Seattle, discusses the recent data comparing the safety and efficacy of bimekizumab with other disease-modifying antirheumatic drugs (DMARDs) in a cohort of patients with PsA.

Highlights
0:10 Safety and efficacy of bimekizumab in PsA
7:07 Dr. Mease's perspective
8:09 Clinical significance of data
8:39 Strengths/limitations
9:29 Next steps

Link to full article: https://www.hcplive.com/view/philip-j...

#psoriaticarthritis #rheumatology #medicine